Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients
Authors:
- 1 May 2020
- journal article
- letter
- Published by Elsevier in Joint Bone Spine
- Vol. 87 (3) , 267-269
Abstract
No abstract availableKeywords
Funding Information
- Merck Sharp and Dohme France
- Pfizer
- UCB
This publication has 7 references indexed in Scilit:
- Predictors of patient decision to discontinue anti-rheumatic medication in patients with rheumatoid arthritis: results from the Ontario best practices research initiativeClinical Rheumatology, 2017
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateAnnals of the Rheumatic Diseases, 2017
- The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiologyPharmacoepidemiology and Drug Safety, 2017
- Persistence with biologic agents for the treatment of rheumatoid arthritis in JapanPatient Preference and Adherence, 2016
- Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistenceRheumatology International, 2016
- Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practiceJoint Bone Spine, 2014
- TNFα antagonist continuation rates in 442 patients with inflammatory joint diseaseJoint Bone Spine, 2007